Endoscopic Sleeve Gastroplasty Is Cost Saving Versus Semaglutide
By Elana Gotkine HealthDay Reporter
FRIDAY, April 12, 2024 -- For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA Network Open.
Muhammad Haseeb, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined the cost-effectiveness of semaglutide versus ESG over five years among individuals with class II obesity (body mass index [BMI], 35 to 39.9 kg/m2) in an economic evaluation study. A Markov cohort model was used to compare ESG and semaglutide, with a baseline strategy of no treatment.
The researchers found that during a five-year time horizon, ESG was more cost-effective than semaglutide, with an incremental cost-effectiveness ratio of −$595,532 per quality-adjusted life year (QALY). Relative to semaglutide, ESG added 0.06 QALYs and reduced the total cost by $33,583. On one-way and probabilistic sensitivity analyses, the results remained robust. Over five years, ESG sustained greater weight loss versus semaglutide (BMI of 31.7 versus 33.0 kg/m2). The annual price of semaglutide, currently $13,618, would need to be $3,591 to achieve nondominance.
"This economic evaluation study suggests that ESG is cost saving compared with semaglutide for class II obesity," the authors write. "This finding is due to the increased effectiveness and lower costs of ESG and the increased dropout rates over time with semaglutide."
Several authors disclosed ties to the biopharmaceutical, medical device, and health care industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2024
Read this next
At 10 Years, Roux-en-Y Gastric Bypass Superior for Patient Excess BMI Loss
MONDAY, Feb. 24, 2025 -- The long-term outcomes of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) may differ in intention-to-treat (ITT) and per protocol (PP)...
Patients With Diabetes Have Comparable Health Expenses After RYGB or Sleeve Gastrectomy
TUESDAY, Jan. 28, 2025 -- For patients with diabetes undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), overall expenditures decrease in the postsurgical...
Racial, Sex Disparities Seen in Discussion of, Progression to Weight Loss Surgery
FRIDAY, Jan. 17, 2025 -- There are racial and sex disparities in the discussion of and progression to metabolic and bariatric surgery (MBS) among eligible patients, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.